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Abstract Our previous studies have shown that the HMG-CoA
reductase (HCR) inhibitor (HCRI), simvastatin, causes myo-
pathy in rabbits and kills L6 myoblasts. The present study was
designed to elucidate the molecular mechanism of HCRI-induced
cell death. We have demonstrated that simvastatin induces the
tyrosine phosphorylation of several cellular proteins within
10 min. These phosphorylations were followed by apoptosis, as
evidenced by the occurrence of internucleosomal DNA fragmen-
tation and by morphological changes detected with Nomarski
optics. Simvastatin-induced cell death was prevented by tyrosine
kinase inhibitors. The MTT assay revealed that the addition of
mevalonic acid into the culture medium partially inhibited
simvastatin-induced cell death. Thus, these results suggested
that protein tyrosine phosphorylation might play an important
role in the intracellular signal transduction pathway mediating
the HCRI-induced death of myoblasts.
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1. Introduction
3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HCR)
is known to be rate limiting in the biosynthesis of cholesterol.
Therefore, its inhibitor (HCRI) is a powerful and widely used
drug for the treatment of hypercholesterolemia [1,2]. HCR
catalyzes the conversion of HMG-CoA to mevalonate, which
is an important precursor of all isoprenoids. Isoprenoids serve
as important lipids for the normal posttranslational modi¢ca-
tion of membrane-associated proteins such as Ras and Rac.
Lovastatin, a lipophilic HCRI, is reported to block cell cy-
cling in G1 and G2/M phase progression and therefore sup-
press the growth of tumors in vitro [3,4]. Our previous studies
have revealed that simvastatin, another lipophilic HCRI, but
not pravastatin, a hydrophilic HCRI, causes electrical myoto-
nia and muscle cell degeneration in intact rabbits and kills L6
myoblasts in culture [5^7]. The L6 myoblast cell line was
originally developed from rat thigh muscle [8] and has re-
tained the characteristics of skeletal muscle [9]. Interestingly,
intracellular Ca2 mobilization from the Ca2 pool in the cell
preceded cell death, suggesting that Ca2 mobilization is in-
volved in the cell killing mechanism in L6 myoblasts [7].
Increased tyrosine phosphorylation caused by increased ac-
tivity of either tyrosine kinases or by decreased activity of
protein tyrosine phosphatase has been shown to play a pivotal
role in the intracellular signal transduction pathway of many
extracellular signals for cellular proliferation and di¡erentia-
tion [10]. It has been suggested that protein tyrosine phos-
phorylation is also involved in the signal transduction path-
way mediating apoptosis in blood cancer cells [11].
In this study, we examined the intracellular signalling events
mediating HCRI-induced cell death in L6 myoblasts as a
model system. Simvastatin rapidly induces the tyrosine phos-
phorylation of cellular proteins in L6 myoblasts, and then
causes apoptotic cell death. Herbimycin A and genistein, in-
hibitors of protein tyrosine kinases, prevented the occurrence
of simvastatin-induced myoblasts cell death. These results
strongly suggest that tyrosine phosphorylation might play
an important role in the development of myopathy by
HCRI in vivo.
2. Materials and methods
2.1. Cell culture and treatment
L6 myoblasts were cultured as monolayers in culture dishes with
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 7.5% fetal
calf serum (FCS) and 100 U/ml penicillin and 100 Wg/ml streptomycin
[7]. Cells were treated with various concentrations of simvastatin (a
generous gift from Sankyo Pharmaceutical Co. Ltd.) for appropriate
periods of time at 37‡C. Control sister cultures were prepared in a
similar way except for the absence of simvastatin. In some experi-
ments, the cells were pretreated with protein tyrosine kinase inhibitors
such as herbimycin A (10 WM) (BioMol, USA) and genistein (75 WM)
(Extrasynthese, France) for 1 h. The cells were then exposed to sim-
vastatin. For morphological studies, L6 myoblasts were cultured
either in 12-well culture plates or on coverslips at 37‡C [12,13]. For
Nomarski optic observations, cell monolayers grown on special cover-
slips (Flexyperm, Toyobo Engineering Co. Ltd., Tokyo, Japan) were
examined under di¡erential interference contrast optics of Nomarski
type (confocal laser microscope, Olympus, Tokyo, Japan) as reported
previously [14].
2.2. MTT assay
To estimate the survival rate of L6 myoblasts treated with simvas-
tatin, the colorimetric 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazo-
lium bromide (MTT) reduction assay was performed on cells treated
with simvastatin or with simvastatin plus mevalonate (0.1, 1 mM) ac-
cording to the method of Jacobson and Evans [15].
2.3. DNA extraction and electrophoresis
After exposure to simvastatin for the indicated times at 37‡C with
or without preincubation with tyrosine kinase inhibitors, total cellular
DNA was extracted from the cells and quantitated by spectrophoto-
metric absorption at 260 nm as described [13]. Total DNA (10 Wg) was
loaded onto a 1.8% agarose gel and run at 50 V, then stained with
ethidium bromide and examined under UV light.
2.4. Detection of protein tyrosine phosphorylation and immunoblot
analysis
L6 myoblasts were exposed to 30 Wg/ml of simvastatin for the in-
dicated times. Then cells were rinsed brie£y with chilled phosphate-
bu¡ered saline (PBS) containing 1 mM p-nitrophenylphosphate and
lysed with SDS sample bu¡er [16]. The samples were heated at 100‡C
for 2 min and equal amounts of protein (100 Wg per lane) were sub-
jected to 10% SDS-PAGE followed by transfer to polyvinylidene di-
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£uoride (PVDF) membranes as previously described [16]. Protein ty-
rosine phosphorylation was detected with an antibody against phos-
photyrosine (K-pY, 4G10, UBI, USA) using the ECL detection system
(Amersham, UK) [12,13,16]. Protein concentration was determined
using the Bradford reagent (Bio-Rad) with Q-globulin as a standard
[17].
2.5. Assay of protein tyrosine phosphatase activity
Protein tyrosine phosphatase activity was assayed according to the
method of Youse¢ et al. [18]. Brie£y, 2U106 cells were incubated with
various concentrations of simvastatin for the indicated times at 37‡C.
The cell pellets were lysed on ice for 15 min using 20 Wl of TKM
bu¡er (50 mM Tris, pH 7.5/25 mM KCl/5 mM MgCl2/1 mM EGTA)
containing 0.5% Triton X-100, 1 mM phenylmethylsulfonyl £uoride,
and 10 Wg/ml leupeptin. After centrifugation at 14 000 rpm for 15 min
at 4‡C, the supernatant was diluted 10-fold with TKM bu¡er without
Triton X-100. Aliquots of 100 Wl were distributed in a 96-well plate
and 10 mM p-nitrophenylphosphate was added and the plate incu-
bated for 30 min at room temperature. The phosphatase activity was
estimated by measuring the absorbance of p-nitrophenol at 405 nm.
3. Results
3.1. Morphology
We examined the morphology of simvastatin-treated L6
myoblasts by Nomarski optics and phase contrast micros-
copy. In the absence of simvastatin, the cells were spindle-
shaped in appearance with normal nuclei (Fig. 1-1). On the
other hand, in the presence of simvastatin, the cells showed
some intracytoplasmic vacuolations and a rounded phenotype
within 1 h (Figs. 1-2 and 2-2). When estimated by the trypan
blue dye exclusion assay, more than 90% of the cells treated
with 30 Wg/ml simvastatin appeared to be dead by 2 h after its
addition. At a lower concentration of simvastatin, it took a
longer time to detect these morphological changes. In con-
trast, a hydrophilic HCRI, pravastatin, which cannot enter
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Fig. 1. Morphology of simvastatin-treated L6 myoblasts examined
by Nomarski optics. L6 myoblasts were cultured on special cover-
slips with regular culture medium and were treated with either
30 Wg/ml simvastatin (2), 60 Wg/ml pravastatin (3) or left untreated
for 1 h at 37‡C (1). These cells were examined under di¡erential
contrast optics of the Nomarski type. Note that simvastatin-treated,
but not pravastatin-treated cells, showed nuclear refractory and cy-
toplasmic vacuolation.
Fig. 2. Herbimycin A e¡ect on morphological degeneration and
DNA fragmentation induced by simvastatin. L6 myoblasts were pre-
treated with 10 WM herbimycin A, a potent protein tyrosine kinase
inhibitor, for at least 3 h at 37‡C (1), then exposed to either simvas-
tatin (30 Wg/ml) (1 and 2) or pravastatin (60 Wg/ml) (3) for 30 min.
These cells were examined by phase contrast microscopy (A) and by
agarose gel electrophoresis of DNA (B). C: Agarose gel electropho-
resis of DNA obtained from cells treated with 60 Wg/ml pravastatin
for either 30 (2) or 60 min (3) and treated with either 3 Wg/ml (4)
or 30 Wg/ml simvastatin (5, 6) for either 30 (5) or 60 min (4, 6).
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the cells, did not cause any morphological changes (Figs. 1-3
and 2-3). Pretreatment of the cells with protein kinase inhib-
itors such as herbimycin A (10 WM) (Fig. 2-1) or genistein
(75 WM) (data not shown) for at least 3 h at 37‡C prevented
these morphological alterations induced by simvastatin. These
concentrations have been shown to inhibit cellular protein
tyrosine kinases in other systems [19,20].
3.2. DNA fragmentation
We extracted total DNA from L6 myoblasts cultured in the
presence of simvastatin (3 and 30 Wg/ml) for various times. We
detected an internucleosomal fragmentation pattern typical
for apoptosis as early as 30 min after addition of 30 Wg/ml
simvastatin (Fig. 2-B2 and C5). At a lower concentration of
simvastatin (3 Wg/ml), we detected internucleosomal DNA
fragmentation 60 min after addition, as we did with the higher
concentration (30 Wg/ml) (Fig. 2-C4 and C6). Pravastatin (60
Wg/ml), a hydrophilic HCRI, failed to induce DNA laddering
even 60 min after its addition to culture medium (Fig. 2-B3
and C3). At concentrations higher than 60 Wg/ml of simvas-
tatin, we observed a smearing of DNA on agarose gels, which
suggests necrotic cell death. On the other hand, we did not
observe such DNA laddering in herbimycin A-pretreated cells
(Fig. 2-B1 and C2).
3.3. MTT assay
We also examined cell survival by the MTT assay of cells
treated with simvastatin. Simvastatin treatment for 45 min
reduced the numbers of living cells to about 30% of control,
whereas supplementation with 1 mM mevalonate, a product
of the HMG-CoA reductase, rescues cells up 80% of the cells
(Fig. 3).
3.4. Protein tyrosine phosphorylation and immunoblot analysis
To determine whether or not protein tyrosine phosphoryla-
tion is involved in the intracellular signal transduction path-
way leading to cell death, we examined the change in total
cellular protein tyrosine phosphorylation with an anti-phos-
photyrosine (a-pY) antibody. Tyrosine phosphorylation of
several proteins with molecular weights of 140^150 kDa,
120^130 kDa, 110 kDa, 70^80 kDa, 50^60 kDa, and 40
kDa was observed at a concentration of 30 Wg/ml simvastatin
within 10 min after its addition to culture medium (Fig. 4-A4).
Even as little as 0.3 Wg/ml simvastatin clearly induced tyrosine
phosphorylation of several proteins (Fig. 4-A2). The time
course of the activation of tyrosine phosphorylation by sim-
vastatin showed a maximum at 10 min after addition (Fig. 4-
B4). On the other hand, pravastatin did not induce protein
tyrosine phosphorylation (Fig. 4-C). Moreover, addition of
di¡erent concentrations of mevalonate to the culture medium
caused a decrease of simvastatin-induced tyrosine phosphor-
ylation in a dose-dependent manner (Fig. 4-C).
3.5. PTPase activity
To elucidate the molecular mechanism for simvastatin-in-
duced tyrosine phosphorylation, we assayed PTPase activity
in simvastatin-treated cells. No inhibition of PTPase activity
was observed (Fig. 5).
4. Discussion
The most important ¢nding of this study is that simvastatin
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Fig. 3. Survival of simvastatin-treated L6 myoblasts. Cell survival
was measured by the MTT assay. Each point represents the percent-
age mean aborbance þ S.D. from three wells against the mean ab-
sorbance at 0 time. The cells were preincubated with 0.1 mM and
1 mM mevalonate (SV+MA(0.1), SV+MA(1)) for 30 min before the
addition of 30 Wg/ml simvastatin (SV, SV+MA(0.1), SV+MA(1)) or
left untreated (control).
Fig. 4. Simvastatin e¡ect on tyrosine phosphorylation of cellular
proteins. A: L6 myoblasts were treated with 0.3 Wg/ml (2), 3 Wg/ml
(3), 15 Wg/ml (4), and 30 Wg/ml (5) simvastatin or left untreated (1)
for 10 min at 37‡C. Total cell-free lysates were obtained as de-
scribed in Section 2 and subjected to 10% SDS-PAGE, transferred
to PVDF membranes and probed with an anti-pY antibody. B: L6
myoblasts were pretreated with 10 Wg/ml herbimycin A (1) or left
untreated (2^6), then treated with (1, 3^6) or without (2) 30 Wg/ml
simvastatin for 5 min (3), 10 min (1, 4), 30 min (5), and 60 min (6).
Then, these cells were washed with chilled PBS containing p-nitro-
phenylphosphate and lysed with SDS sample bu¡er. Samples were
normalized for protein and 100 Wg were subjected to 12.5% SDS-
PAGE followed by Western blotting probed with an anti-pY anti-
body. C: L6 myoblasts were precultured in the presence or absence
of with 0.5 mM (4) and 1 mM (5) mevalonate for 30 min at 37‡C
and then with pravastatin (60 Wg/ml) (1) or simvastatin (30 Wg/ml)
(2, 4, 5) for 10 min or left untreated (3) at 37‡C. Lines on the left
side of each panel represent positions of molecular weight markers
(107 kDa, 68 kDa, 46 kDa, 28 kDa for A, and 107 kDa, 68 kDa,
46 kDa for B and C). The data represent a typical response from
three di¡erent samples with similar results.
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rapidly induces tyrosine phosphorylation of several cellular
proteins even before any morphological change becomes ap-
parent, and well before any induction of apoptotic cell death.
Herbimycin A or genistein, speci¢c inhibitors of protein tyro-
sine kinases, showed an inhibitory e¡ect on protein tyrosine
phosphorylation induced by simvastatin, and a subsequent
inhibition of DNA fragmentation and cell death. These results
suggest a close relationship between protein tyrosine phos-
phorylation and the induction of apoptosis by simvastatin.
In other words, these data strongly suggest that the simvas-
tatin-induced protein tyrosine phosphorylation response is an
obligatory signal transduction mechanism for cell death but
not a signal for protecting themselves. Tyrosine phosphoryla-
tion is known to be regulated by either protein tyrosine kinase
or protein tyrosine phosphatase activity. The simvastatin-in-
duced tyrosine phosphorylation observed here is probably due
to the activation of protein tyrosine kinase(s), because simvas-
tatin apparently did not a¡ect protein tyrosine phosphatase
activity. Such an obligatory role of protein tyrosine phosphor-
ylation in cell death has been observed only in blood cells and
ovarian tumor cell systems [11,18,21,22].
What is the primary target of simvastatin on L6 myoblasts?
First of all, we should remember that only the lipophilic form
of HCRI, which can cross the plasma membrane, can induce
the apoptotic cell death of L6 myoblasts. Pravastatin, a hy-
drophilic HCRI, did not induce any biological e¡ect on these
cells. Pravastatin is known to be unable to get into the cells
unless its speci¢c receptor is expressed on the plasma mem-
brane. These results might indicate that simvastatin does its
job inside the cells. Previous studies employing a lipophilic
HCRI also revealed apoptotic cell death in cells other than
muscle cells (i.e. brain tumor cells and leukemic cells) [4,23].
These reports highlighted the signi¢cance of the impaired ma-
turation of Ras protein in the event of an apoptotic cell death,
because HCRI induced inhibition of the isoprenylation of Ras
protein and, therefore, the Ras protein could not be properly
targeted to the plasma membrane. Such inhibition in the tar-
geting of the Ras protein to the plasma membrane in turn
disrupts Ras-mediated signal transduction in the cells,
although these previous reports did not look for changes in
cellular protein tyrosine phosphorylation. In this study, we
examined the e¡ect of the addition of mevalonate to the cul-
ture medium and found that it rescues cells from simvastatin-
induced cell death incompletely but signi¢cantly, and that it
inhibits simvastatin-induced tyrosine phosphorylation of cel-
lular proteins, as well. These results indicate that the impair-
ment in the biosynthesis of mevalonate and the possible dec-
rement of isoprenoids caused by simvastatin makes a major
contribution the development of cell death, although we can-
not exclude the possibility of a direct e¡ect on protein tyrosine
kinase(s). We recently observed a decreased amount of Ras
protein in the plasma membrane fraction in simvastatin-
treated L6 myoblasts within 10 min after its treatment [24].
These observations strongly suggest that simvastatin caused
an impairment of the Ras-mediated intracellular signaling
pathway. Previous studies have indicated that the intracellular
signaling cascade involving growth factor-induced MAPK ac-
tivation is dependent on the sequential activation of receptor-
type tyrosine kinase-Ras-Raf 1-MEK (MAPK kinase) [25]. It
is now well known that this pathway plays a critical role in
signaling for cell proliferation and survival as well as for cel-
lular di¡erentiation. Therefore, it is reasonable to assume that
a change in protein tyrosine phosphorylation and a loss of the
Ras-mediated signaling cascade work cooperatively to kill the
cells. The relationship between tyrosine phosphorylation of
cellular proteins and an impairment of the Ras-mediated in-
tracellular signaling pathway is not clear at present. We are
now engaged in trying to determine the target(s) of this tyro-
sine phosphorylation response, which might reveal the molec-
ular mechanism by which tyrosine phosphorylation can inter-
act with Ras-mediated signaling in the cells.
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